LELaura Ermellino

Laura Ermellino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Ermellino has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation.

    by Ana Alcaraz-Serna, Noémie Chillier, Aurélien Trompette, Laura Ermellino, Raphaël Porret, Erica Lana, Rebecca Cecchin, Apiha Shanmuganathan, Seher Guney, Oscar Alfageme-Abello, et al.

    Asthma is a deadly chronic respiratory disease affecting over 300 million people. While allergen immunotherapy remains the only disease-modifying treatment, it is poorly applicable for patients with severe asthma. Here, we explored the therapeutic potential of regulatory T cells (Tregs) armed with chimeric allergen receptors-named CAlleR-redirected against the major allergen of birch pollen Bet v1. Four novel anti-Bet v1 antibodies were identified and used to engineer and functionally validate CAlleR. CAlleR Tregs showed specific in vitro activation and suppression and significantly reduced the airway hyperresponsiveness in birch pollen-sensitized mice. Mechanistically, CAlleR Tregs migrated to the lungs and mediastinal lymph nodes, interacted with CD11c+ dendritic cells, and were activated in a FcγR-dependent manner by cross-presenting Bet v1 stabilized with noncompetitive anti-Bet v1 antibodies. These findings unveil a novel mechanism for targeting soluble antigens and highlight the potential of CAlleR Tregs to prevent and treat severe allergies.


  • Open Access

    Targeting PD-1 + T cells with chimeric antigen receptors to reduce the HIV reservoir

    by Laura Ermellino, Riddhima Banga, Spiros Georgakis, Nicole P. Kadzioch, Francesco Procopio, Ana Alcaraz-Serna, Oscar Alfageme-Abello, Raphaël Porret, Rebecca Cecchin, Michail Orfanakis, et al.

    The unique ability of chimeric antigen receptor (CAR) T cells to infiltrate tissues is revolutionizing our perspectives for tackling severe, refractory and otherwise untreatable diseases. In HIV, CAR-T cells have been designed to target viral biomarkers, with limited success so far. Here, we investigated the possibility of redirecting CAR-T cells against a cellular biomarker of the HIV reservoir, the programmed cell death protein 1 (PD-1). We designed two second-generation 4-1BB-CARs using the scFv of either a blocking (bPD1-CAR) or a nonblocking (nbPD1-CAR) anti–PD-1 monoclonal antibody. The CAR avidity modulated T cell sensitivity, trogocytosis, and effector functions, independently of the PD-1 signaling domain. Both anti–PD-1 CAR-T cells could persist for 70 days in HIV-infected humanized mice, correlating with viral protection and a disruption of the lymphoid architecture in the white pulp of the spleen. Together, our results open strategic avenues for reducing the HIV reservoir by demonstrating the feasibility of depleting specific T cell subpopulations.

  • Open Access

    Targeting PD-1 + T-cells with Chimeric Antigen Receptors to reduce the HIV Reservoir

    by Laura Ermellino, Riddhima Banga, Spiros Georgakis, Nicole P. Kadzioch, Francesco Procopio, Ana Alcaraz-Serna, Oscar Alfageme-Abello, Raphaël Porret, Rebecca Cecchin, Michail Orfanakis, et al.

    The unique ability of chimeric antigen receptor (CAR) T-cells to infiltrate tissues is revolutionizing our perspectives for tackling severe-refractory and otherwise untreatable diseases. In HIV, CAR-T-cells have been designed to target viral biomarkers, with limited success so far. Here, we investigated the possibility of redirecting CAR-T-cells against a cellular biomarker of the HIV reservoir, PD-1. We designed two second-generation 4-1BB-CARs using the scFv of either a blocking (bPD1-CAR) or a nonblocking (nbPD1-CAR) anti-PD-1 monoclonal antibody. The CAR avidity modulated T-cell sensitivity, trogocytosis, and effector functions, independently of the PD-1 signalling domain. Both anti-PD-1 CAR T-cells could persist for 70 days in HIV-infected humanized mice, correlating with viral protection and a disruption of the lymphoid architecture in the white pulp of the spleen. Altogether, our results open new strategic avenues for reducing the HIV reservoir as we demonstrate the feasibility of depleting specific T-cell subpopulations. Summary: T cells can be redirected against cellular rather than viral-specific biomarkers to reduce the HIV reservoir.

  • T cell receptor precision editing of regulatory T cells for celiac disease

    by Raphaël Porret, Ana Alcaraz-Serna, Benjamin Peter, Jeremiah Bernier-Latmani, Rebecca Cecchin, Oscar Alfageme-Abello, Laura Ermellino, Morteza Hafezi, Eleonora Pace, M. Fleur du Pré, et al.

    Celiac disease, a gluten-sensitive enteropathy, demonstrates a strong human leukocyte antigen (HLA) association, with more than 90% of patients carrying the HLA-DQ2.5 allotype. No therapy is available for the condition except for a lifelong gluten-free diet. To address this gap, we explored the therapeutic potential of regulatory T cells (T regs ). By orthotopic replacement of T cell receptors (TCRs) through homology-directed repair, we generated gluten-reactive HLA-DQ2.5–restricted CD4 + engineered (e) T effector cells (T effs ) and eT regs and performed in vivo experiments in HLA-DQ2.5 transgenic mice. Of five validated TCRs, TCRs specific for two immunodominant and deamidated gluten epitopes (DQ2.5-glia-α1a and DQ2.5-glia-α2) were selected for further evaluation. CD4 + eT effs exposed to deamidated gluten through oral gavage colocalized with dendritic and B cells in the Peyer’s patches and gut-draining lymph nodes and specifically migrated to the intestine. The suppressive function of human eT regs correlated with high TCR functional activity. eT regs specific for one epitope suppressed the proliferation and gut migration of CD4 + eT effs specific for the same and the other gluten epitope, demonstrating bystander suppression. The suppression requires an antigen-specific activation of eT regs given that polyclonal T regs failed to suppress CD4 + eT effs . These findings highlight the potential of gluten-reactive eT regs as a therapeutic for celiac disease.


  • Cerpegin-derived furo[3,4-c]pyridine-3,4(1H,5H)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibition

    by Simon Hayek, Nicolas Pietrancosta, Anna A. Hovhannisyan, Rodolphe Alves de Sousa, Nassima Bekaddour, Laura Ermellino, Enzo Tramontano, Stéphanie Arnould, Claude Sardet, Julien Dairou, et al.